The antibodies directed against HER2 specifically transport the cytotoxic agent to the tumor cell, where the toxin—in this case a topoisomerase inhibitor—is cleaved and internalized to exert its cytotoxic effect. The gene discussed is ERBB2; the disease is neoplasm.